Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 10, 2012, Pages 1117-1128

  Rodríguez Torres, Maribel ^a,b  

^a Fundación de Investigación   (Puerto Rico)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

chronic hepatitis C; direct acting antiviral; drug drug interactions; HIV HCV coinfection

Indexed keywords

ABACAVIR; ALCOHOL; ALFUZOSIN; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; CISAPRIDE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ERGOT DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA; PIMOZIDE; PLACEBO; RALTEGRAVIR; RIBAVIRIN; RIFAMPICIN; RITONAVIR; STAVUDINE; TELAPREVIR; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIZZINESS; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATTY LIVER; GALLSTONE; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL TOXICITY; MIXED INFECTION; NAUSEA; NEUTROPENIA; NODULAR HYPERPLASIA; PORTAL HYPERTENSION; PRURITUS; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; COINFECTION; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; OLIGOPEPTIDES; PROLINE; TREATMENT OUTCOME;

EID: 84870600663     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.107     Document Type: Review

References (85)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44(Suppl. 1), S6-S9 (2006).
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodefciency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin. Infect. Dis. 34(6), 831-837 (2002).
3. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodefciency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin. Infect. Dis. 29(1), 150-154 (1999).
4. Danta M, Brown D, Bhagani S et al. HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21(8), 983-991 (2007).
5. Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005-2010. MMWR Morb. Mortal. Wkly Rep. 60(28), 945-950 (2011).
6. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52(4), 1497-1505 (2010).
7. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 136, 1609-1617 (2009).
8. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin. Infect. Dis. 49 (10), 1605-1615 (2009).
9. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 (4), 450-456 (2000).
10. Thomas DL, Astemborski J, Vlahov D et al. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 181(3), 844-851 (2000).
11. Graham CS, Baden LR, Yu E et al. Infuence of human immunodefciency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33(4), 562-569 (2001).
12. Goedert JJ, Eyster ME, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100(5), 1584-1589 (2002).
13. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J. Viral Hepat. 14(6), 371-386 (2007).
14. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438-450 (2004).
15. Hadziyannis SJ, Sette H Jr, Morgan TR et al. PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346-355 (2004).
16. Laguno M, Murillas J, Blanco JL et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18(13), F27-F36 (2004).
17. McLaren M, Garber G, Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can. J. Gastroenterol. 22(2), 133-137 (2008).
18. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment. Pharmacol. Ther. 24(4), 585-591 (2006).
19. Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol. Clin. Exp. Res. 30(9), 1520-1526 (2006).
20. Bräu N, Salvatore M, Ríos-Bedoya CF et al. Slower fbrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J. Hepatol. 44(1), 47-55 (2006).
21. Marcellin F, Préau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin. Trials 8(5), 320-327 (2007).
22. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J. Int. AIDS Soc. 14, 22 (2011).
23. Sulkowski MS, Mehta SH, Torbenson MS et al. Rapid fbrosis progression among HIV/hepatitis C vir us-co-infected adults. AIDS 21(16), 2209-2216 (2007).
24. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF et al. Effect of hepatitis C virus treatment in fbrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodefciency virus: a paired liver biopsy study. J. Hepatol. 46(4), 613-619 (2007).
25. Carrat F, Bani-Sadr F, Pol S et al. ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon CC-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292(23), 2839-2848 (2004).
26. Chung RT, Andersen J, Volberding P et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon (X-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451-459 (2004).
27. Labarga P, Vispo E, Barreiro P et al. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. J. Acquir. Immune De fc. Syndr. 53(3), 364-368 (2010).
28. Berenguer J, Alvarez-Pellicer J, Martín PM et al. GESIDA3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodefciency virus and hepatitis C virus. Hepatology 50(2), 407-413 (2009).
29. Labarga P, Soriano V, Vispo ME et al Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J. Infect. Dis. 196(5), 670-676 (2007).
30. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus:2007 updated recommendations from the HCV-HIV International Panel. AIDS 21(9), 1073-1089 (2007).
31. Thompson MA, Aberg JA, Cahn P et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection:2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3), 321-333 (2010).
32. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J. Infect. Dis. 197(Suppl. 3), S279-S293 (2008).
33. Pascual-Pareja JF, Caminoa A, Larrauri C et al. HAART is associated with lower hepatic necroinfammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS 23(8), 971-975 (2009).
34. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 4(2), e4517 (2009).
35. Sulkowski MS. Viral hepatitis and HIV coinfection. J. Hepatol. 48(2), 353-367 (2008).
36. Maida I, Garcia-Gasco P, Sotgiu G et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir. Ther. (Lond.) 13(1), 103-107 (2008).
37. Vispo E, Barreiro P, Pineda JA et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir. Ther. 13(3), 429-437 (2008).
38. Solas C, Pambrun E, Winnock M et al.; The ANRS CO-13 HEPAVIH Study Group. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fction? AIDS doi:10.1097/QAD.0b013e32835763a4 (2012) (Epub ahead of print).
39. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther. (Lond.) 12 (7), 1075-1085 (2007).
40. de Mendoza C, Martin-Carbonero L, Barreiro P et al. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. AIDS 21(5), 583-588 (2007).
41. Reiberger T, Kosi L, Maresch J et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy J. Infect. Dis. 202(1), 156-160 (2010).
42. Sherman KE, Rouster SD, Stanford S et al. AIDS Clinical Trials Group 5071 Study Team. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with inter fer on-based regimens. J. Infect. Dis. 201(5), 712-719 (2010).
43. Martin-Carbonero L, Nuñez M, Mariño A et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 22(1), 15-21 (2008).
44. Opravil M, Sasadeusz J, Cooper DA et al. Effect of baseline CD4 cell count on the effcacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J. Acquir. Immune Defc. Syndr. 47(1), 36-49 (2008).
45. Mira JA, Gutiérrez-Valencia A, Gil Ide L et al. Effcacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin. Infect. Dis. 49(8), e84-e91 (2009).
46. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
47. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-CC and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
48. McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138(7), 2307-2314 (2010).
49. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-(X and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
50. Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fbrosis progression and response to treatment. Liver Int. 31(4), 443-460 (2011).
51. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-a and ribavirin. Aliment. Pharmacol. Ther. 36(2), 91-103 (2012).
52. Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT; AIDS Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 6(10), e25753 (2011).
53. Payer BA, Reiberger T, Aberle J et al. Vienna HIV-HCV study group. IL28B and interferon-y inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur. J. Clin. Invest. 42(6), 599-606 (2012).
54. Qu J, Zhang Q, Li Y et al. The Tat protein of human immunodefciency virus-1 enhances hepatitis C virus replication through interferon y-inducible protein-10. BMC Immunol. 13, 15 (2012).
55. Medrano J, Neukam K, Rallón N et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV Clin. Infect. Dis. 51(10), 1209-1216 (2010).
56. Suppiah V, Gaudieri S, Armstrong NJ et al.; International Hepatitis C Genetics Consortium (IHCGC). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med. 8(9), e1001092 (2011).
57. Van den Eynde E, Crespo M, Esteban JI et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin. Infect. Dis. 48(8), 1152-1159 (2009).
58. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4), 1433-1444 (2011).
59. Deming P, McNicholl IR. Coinfection with human immunodefciency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31(4), 357-368 (2011).
60. Osinusi A, Rasimas JJ, Bishop R et al. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J. Acquir. Immune Defc. Syndr. 53(3), 357-363 (2010).
61. Bhattacharya D, Umbleja T, Carrat F et al. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J. Acquir. Immune Defc. Syndr. 55(2), 170-175 (2010).
62. de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am. J. Transplant. 6(12), 2983-2993 (2006).
63. Pineda JA, Romero-Gómez M, Díaz-García F et al. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Hígado. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41(4), 779-789 (2005).
64. Huprikar S. Solid organ transplantation in HIV-infected individuals: an update. Rev. Med. Virol. 19(6), 317-323 (2009).
65. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin. Liver Dis. 26(3), 273-284 (2006).
66. Miró JM, Torre-Cisnero J, Moreno A et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm. Infecc. Microbiol. Clin. 23(6), 353-362 (2005).
67. Samuel D, Duclos Vallee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J. Hepatol. 39(1), 3-6 (2003).
68. Sugawara Y, Tamura S, Kokudo N. Liver transplantation in HCV/HIV positive patients. World J. Gastrointest. Surg. 3(2), 21-28 (2011).
69. Sulkowski M, Pol S, Cooper C et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: interim on-treatment results. Presented at:49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA, 20-23 October 2011.
70. Sulkowski M, Pol S, Cooper C et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients. Presented at:19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5-8 March 2012.
71. Sulkowski M, Dieterich DT, Sherman KE et al. Interim analysis of a phase IIa double-blind study of TVR in combination with peg-IFN-a2a and RBV in HIV/HCV co-infected patients. Presented at:18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011.
72. Sherman KE, Rockstroh JK, Dieterich DT et al. Telaprevir in combination with peginterferon (X-2a/ribavirin in HCV/HIV coinfected patients: a 24-week treatment interim analysis. Presented at:62nd Annual Meeting of the American Association for the Study of Liver Disease. San Francisco, CA, USA, 4-8 November 2011.
73. Dietrich D, Soriano V, Sherman K et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis. Presented at:19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5-8 March 2012.
74. Telaprevir (package insert) INCIVEK™. Vertex Pharmaceuticals Inc., MA, USA (2011).
75. Boceprevir (package insert) VICTRELIS™. Merck & Co., Inc., NJ, USA (2011).
76. Garg V, Kauffman RS, Beumont M, van Heeswijk. Drug interaction profle of Telaprevir. Presented at: HEP DART 2011. Koloa, HI, USA, 4-8 December 2011.
77. Van Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at:18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011.
78. van Heeswijk R, Garg V, Boogaerts G et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. Presented at:51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2011.
79. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. Presented at:18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011.
80. Hulskotte EGJ, Feng HP, Xuan F et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Presented at:19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5-8 March 2012.
81. De Kanter C, Blonk MI, Colbers A et al. Infuence of the HCV protease inhibitor Boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. Presented at:19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5-8 March 2012.
82. Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin. Infect. Dis. 54(7), 979-983 (2012).
83. Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D; FDA Antiviral Products Advisory Committee. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 46(6), 2014-2020 (2007).
84. Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically signifcant drug interactions with antiretroviral therapy. Pharmacotherapy 27(10), 1379-1386 (2007).
85. Rodríguez-Rosado R, García-Samaniego J, Soriano V Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 12(10), 1256 (1998).